Literature DB >> 17475706

Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy.

Olcay Tatar1, Annemarie Adam, Kei Shinoda, Tillmann Eckert, Gábor B Scharioth, Micheal Klein, Efdal Yoeruek, Karl Ulrich Bartz-Schmidt, Salvatore Grisanti.   

Abstract

AIM: To evaluate expression of proangiogenic matrix metalloproteinases (MMP) 2 and 9 at distinct intervals after verteporfin photodynamic therapy (PDT) in human choroidal neovascular membranes (CNV) secondary to age-related macular degeneration (AMD).
METHODS: Retrospective review of an interventional case series of 49 patients who underwent removal of CNV. Twenty-six patients were treated with PDT 3 to 383 days prior to surgery. Twenty-three CNV without previous treatment were used as controls. CNV were stained for CD34, cytokeratin 18, endostatin, MMP-2 and MMP-9 by immunohistochemistry.
RESULTS: CNV without previous therapy disclosed MMP-2, MMP-9 in RPE-Bruch's membrane, vessels and stroma in different intensities. Three days after PDT, MMP-9 expression was significantly weaker in stroma (p = 0.0019). Endostatin was significantly reduced in vessels (p<0.001). At longer post-PDT intervals, a significant increase of MMP-9 in stroma (p = 0.037) and of endostatin in RPE-Bruch's membrane (p = 0.02), vessels (p = 0.005) and stroma (p<0.001) were disclosed. No significant changes in MMP-2 expression were detected.
CONCLUSIONS: PDT induced an early, temporary decrease in MMP-9 and endostatin expression. At longer intervals, MMP-9 increase is possibly associated with the angiogenic process responsible for recurrence after PDT. MMP-9, however, acts as a double-edged sword by concomitant induction of endostatin, an endogenous inhibitor of angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17475706      PMCID: PMC1954910          DOI: 10.1136/bjo.2007.114769

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  51 in total

Review 1.  Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration.

Authors:  U Schmidt-Erfurth; T Hasan
Journal:  Surv Ophthalmol       Date:  2000 Nov-Dec       Impact factor: 6.048

2.  Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin.

Authors:  K Mori; A Ando; P Gehlbach; D Nesbitt; K Takahashi; D Goldsteen; M Penn; C T Chen; K Mori; M Melia; S Phipps; D Moffat; K Brazzell; G Liau; K H Dixon; P A Campochiaro
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

3.  Generation and degradation of human endostatin proteins by various proteinases.

Authors:  M Ferreras; U Felbor; T Lenhard; B R Olsen; J Delaissé
Journal:  FEBS Lett       Date:  2000-12-15       Impact factor: 4.124

Review 4.  Collagen XVIII/endostatin structure and functional role in angiogenesis.

Authors:  U K Zatterstrom; U Felbor; N Fukai; B R Olsen
Journal:  Cell Struct Funct       Date:  2000-04       Impact factor: 2.212

5.  Matrix metalloproteinase (MMP) expression in experimental choroidal neovascularization.

Authors:  A Kvanta; W Y Shen; S Sarman; S Seregard; B Steen; E Rakoczy
Journal:  Curr Eye Res       Date:  2000-09       Impact factor: 2.424

6.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

7.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

Authors:  N M Bressler
Journal:  Arch Ophthalmol       Date:  2001-02

8.  Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase.

Authors:  Y M Kim; J W Jang; O H Lee; J Yeon; E Y Choi; K W Kim; S T Lee; Y G Kwon
Journal:  Cancer Res       Date:  2000-10-01       Impact factor: 12.701

9.  The role of matrix metalloproteinase activity in the maturation of human capillary endothelial cells in vitro.

Authors:  B M Kräling; D G Wiederschain; T Boehm; M Rehn; J B Mulliken; M A Moses
Journal:  J Cell Sci       Date:  1999-05       Impact factor: 5.285

10.  Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices.

Authors:  G E Davis; K A Pintar Allen; R Salazar; S A Maxwell
Journal:  J Cell Sci       Date:  2001-03       Impact factor: 5.285

View more
  12 in total

1.  MMP-2 Rs24386 (C-->T) gene polymorphism and the phenotype of age-related macular degeneration.

Authors:  Rasa Liutkeviciene; Vaiva Lesauskaite; Giedre Sinkunaite-Marsalkiene; Sandrita Simonyte; Reda Zemaitiene; Loresa Kriauciuniene; Dalia Zaliuniene
Journal:  Int J Ophthalmol       Date:  2017-09-18       Impact factor: 1.779

2.  Age-dependent changes in FasL (CD95L) modulate macrophage function in a model of age-related macular degeneration.

Authors:  Hui Zhao; Jayeeta Roychoudhury; Teresa A Doggett; Rajendra S Apte; Thomas A Ferguson
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-08-07       Impact factor: 4.799

3.  The α7-nicotinic acetylcholine receptor and MMP-2/-9 pathway mediate the proangiogenic effect of nicotine in human retinal endothelial cells.

Authors:  Aaron M Dom; Adam W Buckley; Kathleen C Brown; Richard D Egleton; Aileen J Marcelo; Nancy A Proper; Donald E Weller; Yashoni H Shah; Jamie K Lau; Piyali Dasgupta
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-22       Impact factor: 4.799

4.  Doxycycline's effect on ocular angiogenesis: an in vivo analysis.

Authors:  Constance A Cox; Juan Amaral; Rita Salloum; Liliana Guedez; Ted W Reid; Cindy Jaworski; Moly John-Aryankalayil; Ken A Freedman; Mercedes M Campos; Alfredo Martinez; Susan P Becerra; Deborah A Carper
Journal:  Ophthalmology       Date:  2010-06-03       Impact factor: 12.079

5.  Does matrix metalloproteinase-3 polymorphism play a role in age-related macular degeneration in patients with myocardial infarction?

Authors:  Rasa Liutkevičienė; Diana Žaliaduonytė-Pekšienė; Dalia Žaliūnienė; Olivija Gustienė; Vytautas Jašinskas; Vaiva Lesauskaitė; Abdonas Tamošiūnas; Remigijus Žaliūnas
Journal:  Medicina (Kaunas)       Date:  2012       Impact factor: 2.430

6.  Biologically active fibronectin fragments stimulate release of MCP-1 and catabolic cytokines from murine retinal pigment epithelium.

Authors:  Bobbie Ann Austin; Baoying Liu; Zhuqing Li; Robert B Nussenblatt
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-01-17       Impact factor: 4.799

7.  In vitro and in vivo matrix metalloproteinase expression after photodynamic therapy with a liposomal formulation of aminolevulinic acid and its methyl ester.

Authors:  Beata Osiecka; Kamil Jurczyszyn; Krzysztof Symonowicz; Andrzej Bronowicz; Paweł Ostasiewicz; Elzbieta Czapińska; Katarzyna Hotowy; Małgorzata Krzystek-Korpacka; Elzbieta Gebarowska; Ilona Izykowska; Piotr Dziegiel; Grzegorz Terlecki; Piotr Ziółkowski
Journal:  Cell Mol Biol Lett       Date:  2010-09-17       Impact factor: 5.787

8.  Peroxisome proliferator-activated receptor and age-related macular degeneration.

Authors:  Alexandra A Herzlich; Jingsheng Tuo; Chi-Chao Chan
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

9.  Association of exudative age-related macular degeneration with matrix metalloproteinases-2 (-1306 C/T) rs243865 gene polymorphism.

Authors:  Rasa Liutkeviciene; Alvita Vilkeviciute; Dominyka Borisovaite; Goda Miniauskiene
Journal:  Indian J Ophthalmol       Date:  2018-04       Impact factor: 1.848

10.  Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration.

Authors:  Yusuke Arai; Hidenori Takahashi; Satoru Inoda; Xue Tan; Shinichi Sakamoto; Yuji Inoue; Yujiro Fujino; Hidetoshi Kawashima; Yasuo Yanagi
Journal:  PLoS One       Date:  2020-03-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.